Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

SHSE:600671 Stock Report

Market Cap: CN¥1.1b

Hangzhou TianMuShan Pharmaceutical EnterpriseLtd Past Earnings Performance

Past criteria checks 0/6

Hangzhou TianMuShan Pharmaceutical EnterpriseLtd's earnings have been declining at an average annual rate of -34.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 20.3% per year.

Key information

-34.9%

Earnings growth rate

-35.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-20.3%
Return on equity-27.5%
Net Margin-9.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

What Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's (SHSE:600671) 27% Share Price Gain Is Not Telling You

Oct 25
What Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's (SHSE:600671) 27% Share Price Gain Is Not Telling You

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) Investors Are Less Pessimistic Than Expected

Jul 18
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) Investors Are Less Pessimistic Than Expected

Revenue & Expenses Breakdown

How Hangzhou TianMuShan Pharmaceutical EnterpriseLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600671 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24160-15700
30 Jun 24130-33581
31 Mar 24138-39510
31 Dec 23122-38440
30 Sep 23117-65392
30 Jun 23108-70482
31 Mar 23105-71562
31 Dec 22109-68572
30 Sep 22126-45660
30 Jun 22122-45691
31 Mar 22134-33661
31 Dec 21147-30671
30 Sep 21146-52670
30 Jun 21173-44730
31 Mar 21190-44801
31 Dec 20207-41891
30 Sep 20238491044
30 Jun 20260461214
31 Mar 20277521436
31 Dec 19297511535
30 Sep 19287-2014310
30 Jun 19284-181309
31 Mar 19344-91156
31 Dec 18358-101138
30 Sep 1838271200
30 Jun 18353251080
31 Mar 182439870
31 Dec 171768700
30 Sep 1713110480
30 Jun 171182470
31 Mar 171223440
31 Dec 161241460
30 Sep 16104-9500
30 Jun 16102-24480
31 Mar 1695-23460
31 Dec 1595-22420
30 Sep 15104-12390
30 Jun 15107-2380
31 Mar 15132-2420
31 Dec 141493490
30 Sep 141907580
30 Jun 142271660
31 Mar 142480700
31 Dec 132812720

Quality Earnings: 600671 is currently unprofitable.

Growing Profit Margin: 600671 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600671 is unprofitable, and losses have increased over the past 5 years at a rate of 34.9% per year.

Accelerating Growth: Unable to compare 600671's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 600671 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 600671 has a negative Return on Equity (-27.48%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies